IN THE CLAIMS

1 (Currently Amended). A method for prevention of lipid peroxidation in the brain which comprises administering to an individual in need thereof an effective amount of a compound selected from the group consisting of:

(a) a compound of formula I:



(I)

wherein

R^1 is H or hydrocarbyl; R^2 is a hydrophobic radical; R^3 is a radical selected from the group consisting of 3-(C_2-C_6)acyl-4-hydroxyphenyl, 3-hydroxyimino(C_2-C_6)alkyl-4-hydroxyphenyl, ~~or~~ and COOZ, wherein Z is H, (C_1-C_6)alkyl, aryl or ar(C_1-C_6)alkyl; and n is an integer from 1 to 20; and

(b) a compound of formula II:



(II)

wherein

R^4 is (C_1-C_6)acyl, nitro(C_1-C_6)alkyl, cyano(C_1-C_6)alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl or $-CH_2NR^7R^8$, wherein R^7 and R^8, the same or different, is each H or (C_1-C_6)alkyl, or

together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from the group consisting of N, O ~~or~~ and S, the further N atom in such saturated 5-7 membered ring being optionally substituted by (C_1-C_6)-alkyl, (C_1-C_6)-acyl, hydroxy-(C_1-C_6)alkyl, (C_1-C_6)alkoxycarbonyl, and 8-hydroxyquinolin-5-yl-(C_1-C_6)alkyl,

and

either R^5 is H and R^6 is (C_2-C_6)-acyl or hydroxyimino(C_2-C_6)alkyl, or R^5 and R^6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring structure,

or a pharmaceutically acceptable salt of a compound of formula I or II.

2-3 (Cancelled)

4 (Currently Amended). A method according to claim 1, wherein said compound is a compound of formula I wherein n is 2 to 4~~, preferably 2~~; R^1 is H or a saturated, unsaturated or aromatic hydrocarbyl radical~~, preferably selected from C_1-C_8 alkyl, C_2-C_8 alkenyl and phenyl~~; R^2 is a hydrophobic radical selected from the group consisting of (C_6-C_{20})-alkyl, (C_6-C_{20})-alkenyl, a radical selected from the group consisting of (C_5-C_{20})-acyl, benzyloxycarbonyl, substituted benzyloxycarbonyl, (C_3-C_8)-alkoxycarbonyl, cycloalkoxycarbonyl

and aryloxycarbonyl, said radical being either linked directly to the N atom or through a (C_1-C_5)—alkylene chain, and N-substituted amino or 4-substituted-piperazin-1-yl~~e~~ linked to the N atom through a (C_1-C_5)—alkylene chain; and R^3 is a radical selected from the group consisting of 3-(C_2-C_6)acyl-4-hydroxyphenyl, 3-hydroxyimino(C_2-C_6)alkyl-4-hydroxyphenyl, ~~or~~ and COOZ, wherein Z is H, (C_1-C_6)alkyl, aryl or ar(C_1-C_6)alkyl.

5 (Currently Amended). A method according to claim 4, wherein R^2 is straight or branched (C_6-C_{20})—alkyl or alkenyl; saturated or unsaturated (C_5-C_{20})—carboxylic acyl linked directly to the N atom or through a (C_1-C_5)—alkylene chain; benzyloxycarbonyl or halo-substituted benzyloxycarbonyl, ~~such as o- and p-chloro-benzyloxycarbonyl, 2,4- and 2,6-dichlorobenzyloxycarbonyl,~~ linked directly to the N atom or through a (C_1-C_5)—alkylene chain; a bulky alkoxycarbonyl group, ~~such as tert-butoxycarbonyl~~ linked directly to the N atom or through a (C_1-C_5)—alkylene chain; cycloalkoxycarbonyl linked directly to the N atom or through a (C_1-C_5)—alkylene chain; aryloxycarbonyl ~~such as fluorenylmethoxycarbonyl~~, linked directly to the N atom or through a (C_1-C_5)—alkylene chain; or 4-substituted-piperazin-1-yl or N-substituted amino, linked to the N atom through a (C_1-C_5)—alkylene chain, wherein the 4- and N-substituent is a hydrophobic group selected from the group consisting of (C_6-C_{20})—alkyl, (C_6-C_{20})—alkenyl, (C_5-C_{20})—acyl,

benzyloxycarbonyl, substituted benzyloxycarbonyl, (C_3-C_8)-alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, N-substituted amino and 4-substituted-piperazin-1-yl, all such substituents being as defined above.

6 (Currently Amended). A method according to claim 5, wherein n is 2, R^1 is H, R^2 is ~~a~~ the radical -$(CH_2)_3NHCOOCH_2C_6H_5$, 5-(tert-butoxycarbonyl) pentyl, or -$(CH_2)_2$-(4-carbobenzoxy)-piperazin-1-yl, and R^3 is benzyloxycarbonyl, 3-(1-hydroxy-iminoethyl)-4-hydroxyphenyl or 3-acetyl-4-hydroxyphenyl.

7 (Previously Amended). A method according to claim 6, wherein said compound of formula I is selected from the group of compounds consisting of:

N-[2-(4-carbobenzoxypiperazin-1-yl)ethyl]-4,5-bis[bis(benzyloxycarbonylmethyl)amino]valeramide;

N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[bis(3-acetyl-4-hydroxybenzyl)amino]valeramide;

N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[bis(3-(1-hydroxy-iminoethyl)-4-hydroxybenzyl)amino]valeramide; and

N-[5-(tert-butyloxycarbonyl)pentyl]-4,5-bis[(bis(benzyloxycarbonyl)methyl]amino]valeramide.

8 (Currently Amended). A method according to claim 1, wherein said compound is a compound of formula II wherein R^4 is (C_1-C_6)-acyl, nitro(C_1-C_6)alkyl in which the (C_1-C_6)alkyl

group may be branched, cyano(C_1-C_6)alkyl, ~~preferably cyanomethyl,~~ (C_1-C_6)-alkoxy(C_1-C_6)alkyl, ~~preferably methoxymethyl,~~ or $CH_2NR^7R^8$, in which R^7 and R^8 are both H, or one is H and the other is (C_1-C_6)-alkyl, or both R^7 and R^8 are (C_1-C_6) alkyl, or R^7 and R^8 together with the N-atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from the group consisting of N, O ~~or~~ and S, the further N-atom in such saturated 5-7 membered ring being optionally substituted by (C_1-C_6)-alkyl, (C_1-C_6)-acyl, hydroxy-(C_1-C_6)alkyl, (C_1-C_6)-alkoxycarbonyl, ~~and~~ or 8-hydroxyquinolin-5-yl(C_1-C_6) alkyl~~, preferably 8-hydroxyquinolin-5-yl-methyl~~.

9 (Currently Amended). A method according to claim 8, wherein R^4 is a radical selected from the group consisting of formyl, 2-methyl-2-nitropropyl, cyanomethyl, methoxymethyl, (diethyl)amino-methyl, piperidin-1yl~~o~~methyl, morpholin-1-yl~~o~~methyl, thiomorpholin-1-yl~~o~~methyl, piperazin-1-yl~~o~~methyl, imidazolylmethyl, 4-methyl-piperazin-1yl~~o~~methyl, 4-(2-hydroxyethyl)piperazin-1-yl~~o~~methyl, 4-formylpiperazin-1-yl~~o~~methyl, 4-(ethoxycarbonyl)piperazin-1yl~~o~~methyl, 4-(butoxycarbonyl) piperazin-1-yl~~o~~methyl, 4-(8-hydroxyquinolin-5-yl-methyl)-piperazin-1-yl~~o~~methyl, and 4-(8-hydroxy-quinolin-5-yl-methyl) homopiperazin-1-yl~~o~~methyl.

10 (Currently Amended). A method according to claim 8 or 9, wherein, in said compound of formula II, R^5 is H and R^6 is (C_2-C_6)-acyl~~, preferably acetyl,~~ or hydroxyimino(C_2-C_6)alkyl~~, preferably hydroxyiminoethyl~~.

11 (Previously Amended). A method according to claim 10, wherein said compound of formula II is selected from the group of compounds consisting of::

2-acetyl-4-[4-(2-hydroxyethyl)piperazin-1-yl-methyl] phenol; and

2-(1-hydroxyiminoethyl)-4-[4-(2-hydroxyethyl) piperazin-1-ylmethyl]phenol.

12 (Currently Amended). A method according to claim 8 or 9, wherein, in said compound of formula II, R^5 and R^6 together with the phenyl ring form a quinoline ring structure.

13 (Currently Amended). A method according to claim 12, wherein said quinoline compound is selected from the group consisting of:

5-formyl-8-hydroxyquinoline;

5-(2-methyl-2-nitropropyl)-8-hydroxyquinoline;

5-methoxymethyl-8-hydroxyquinoline;

5-diethylaminomethyl-8-hydroxyquinoline;

5-piperidinomethyl-8-hydroxyquinoline;

5-morpholinomethyl-8-hydroxyquinoline;

5-(4-methylpiperazin-1-ylmethyl)-8-hydroxyquinoline;

5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline;

5-[4-ethoxycarbonylpiperazin-1-ylmethyl)-8-hydroxy-quinoline;

5-(imidazol-1-ylmethyl)-8-hydroxyquinolin;

5-(4-Boc-piperazin-1-ylmethyl)-8-hydroxyquinoline;

5-piperazin-1-ylmethyl-8-hydroxyquinoline;

N.N'-di-(8-hydroxyquinolin-5-ylmethyl) piperazine;

5-(4-formylpiperazin-1-ylmethyl)-8-hydroxyquinoline;

5-cyanomethyl-8-hydroxyquinoline;

N.N'-di-(8-hydroxyquinolin-5-ylmethyl) homopiperazine; and

5-thiomorpholin-1-ylmethyl-8-hydroxyquinoline.

14 (Cancelled)

15 (Previously Amended). A method according to claim 1 for the treatment of a neurodegenerative disorder.

16 (Previously Amended). A method according to claim 15 wherein said neurodegenerative disorder is Parkinson's disease.

17 (Previously Amended). A method according to claim 1 for the treatment of stroke.

18-21 (Cancelled)

22 (Currently Amended). A compound of formula I:



(I)

wherein

R^1 is H or hydrocarbyl; R^2 is a hydrophobic radical; R^3 is a radical selected from 3-(C_2-C_6)acyl-4-hydroxyphenyl, 3-hydroxyimino(C_2-C_6)alkyl-4-hydroxyphenyl, or COOZ, wherein Z is H, (C_1-C_6)alkyl, aryl or ar(C_1-C_6)alkyl; and n is an integer from 1 to 20,

excluding the compounds:

N-[5-(tert-butoxycarbonyl)pentyl]-4,5-bis[(bis(benzyloxycarbonyl)methyl]amino]valeramide;

N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[di(methoxycarbonylmethyl)amino]valeramide;

N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[di(benzyloxycarbonylmethyl)amino]valeramide; and

N-(benzyloxycarbonylaminoethyl)-4,5-bis[di(carboxylmethyl)amino]valeramide.

23 (Currently Amended). A compound of formula II:



(II)

wherein

R^4 is (C_1-C_6)acyl, nitro(C_1-C_6)alkyl, cyano(C_1-C_6)alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl or $-CH_2NR^7R^8$, wherein R^7 and R^8, the same or different, is each H or (C_1-C_6)alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom in such saturated 5-7 membered ring being optionally substituted by (C_1-C_6)-alkyl, (C_1-C_6)-acyl, hydroxy-(C_1-C_6)alkyl, (C_1-C_6)alkoxycarbonyl, and 8-hydroxyquinolin-5-yl-(C_1-C_6)alkyl, and

R^5 is H and R^6 is (C_2-C_6)-acyl or hydroxyimino(C_2-C_6)alkyl,

excluding the compounds:

2-hydroxy-5-(dipropylaminomethyl)acetophenone; and

2-hydroxy-5-(dipropylaminomethyl)acetophenone oxime.

24 (Currently Amended). A compound of formula II:



(II)

wherein

R^4 is (C_1-C_6)acyl, nitro(C_1-C_6)alkyl, cyano(C_1-C_6)alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl or $-CH_2NR^7R^8$, wherein R^7 and R^8, the same or different, is each H or (C_1-C_6)alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom in such saturated 5-7 membered ring being optionally substituted by (C_1-C_6)-alkyl, (C_1-C_6)-acyl, hydroxy-(C_1-C_6)alkyl, (C_1-C_6)alkoxycarbonyl, and 8-hydroxyquinolin-5-yl-(C_1-C_6)alkyl, and

R^5 and R^6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring, excluding the quinoline compounds wherein R^4 is (C_1-C_2)acyl, cyanomethyl, (C_1-C_6)alkoxymethyl or $-CH_2NR^7NR^8$, wherein R^7 and R^8 are both H or (C_1-C_6)alkyl, or together with the N atom form a saturated ring selected from the group consisting of pyrrolidino, piperidino, morpholino and piperazino.

25 (New). The compound of claim 22 consisting of N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[bis(3-(1-hydroxy-iminoethyl)-4-hydroxybenzyl) amino] valeramide.

26 (New). The compound of claim 24 consisting of 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

27 (New). A method according to claim 13 which comprises administering to an individual in need thereof an effective amount of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

28 (New). A method according to claim 27 for the treatment of stroke.

29 (New). A method according to claim 27 for the treatment of a neurodegenerative disorder.

30 (New). A method according to claim 29 wherein said neurodegenerative disorder is Parkinson's disease.

31 (New). A method for retarding dopaminergic neuron degeneration in the substantia nigra of the brain which comprises administering to an individual in need thereof an effective amount of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

32 (New). A method according to claim 31 for the treatment of a neurodegenerative disorder.

33 (New). A method according to claim 32 wherein said neurodegenerative disorder is Parkinson's disease.